Objective: Low vitamin D (25 OH vitamin D) is implicated in the development of diabetes and the metabolic syndrome. We examined whether hypovitaminosis D has a clinically significant impact on glycaemia, metabolic status and inflammatory markers in Chinese patients with established type 2 diabetes. Methods: Characteristics of 109 patients aged over 50 years were stratified by 25 OH vitamin D status. Patients identified as 25 OH vitamin D deficient (≤ 50 nmol/L) received cholecalciferol 2,000 IU daily for three months. Measurement of HbA1c, metabolic syndrome parameters, 25 OH vitamin D, calcium, phosphate, PTH, hsCRP and ferritin were taken at baseline and then 25 OH vitamin D, PTH, calcium, phosphate monthly for three months in those on replacement therapy. Results: Vitamin D deficiency was common, affecting 36% of patients. There was no impact of hypovitaminosis D on metabolic syndrome status, HbA1c or insulin use (p ≥ 0.4 for all) and no association between 25OHVitD and ferritin or hsCRP (p ≥ 0.3 for all). Neither BMI nor the metabolic syndrome affected the incremental rise in 25OHVitD levels during supplementation. Conclusion: There is no relationship between hypovitaminosis D and metabolic control or inflammatory markers in established type 2 diabetes. This suggests that at least in Chinese populations, the effect of low vitamin D is not clinically significant once diabetes is established. Future 25OHVitD intervention trials should therefore focus on prevention in pre-diabetes.
Introduction
Accumulating evidence from several cross-sectional studies suggests that lower levels of circulating vitamin D are associated with an increased prevalence of type 2 diabetes and the metabolic syndrome. 1 In the largest epidemiological study from the NHANES population, an inverse dose-dependent effect was seen with lower quartiles of vitamin D in association with the highest number of metabolic syndrome features. 2 The mechanisms that belie such an association have yet to be fully determined. Several lines of evidence suggest a role for vitamin D in insulin secretion, insulin resistance and systemic inflammation, all implicated in the pathogenesis of type 2 diabetes and the metabolic syndrome.
Previous studies have examined vitamin D levels in normal subjects compared with existing type 2 diabetes and with the development of new diabetes disease. These studies are consistent with the notion that insufficient vitamin D may predispose for the development of diabetes. However, whether these associations are still clinically important within the context of established diabetes remains unclear. Furthermore, previous studies have suggested that vitamin D associations appear to be ethnic specific, 2 but few studies have examined these relationships with ethnicity as a criterion for participation. Potentially both duration of established diabetes and ethnicity may impact on vitamin D associations as they present varying contributions of insulin resistance and insulin secretory defects to disease pathogenesis. Additionally, as vitamin D is fat soluble, obesity is a potential confounder and previous associations may simply reflect an inverse association between vitamin D levels and body weight or adiposity.
We hypothesise that if vitamin D has a clinically important effect within established type 2 diabetes and the metabolic syndrome, then hypovitaminosis D would be associated with poorer metabolic control, increased prevalence and severity of the metabolic syndrome and its individual parameters, and a direct association would be seen with markers of systemic inflammation. Thus in this study we examined the impact of low vitamin D levels on metabolic status as well as the relationship between vitamin D levels and ferritin and hsCRP as markers of systemic inflammation. A single ethnic group of Chinese patients with type 2 diabetes was studied as they had the advantage of similar lifestyle and a relatively low level of obesity compared with other populations with diabetes, thus reducing the confounding effect of these factors on circulating vitamin D. All metabolic associations were examined independent of body weight or adiposity.
Methods
A total of 109 Chinese patients with type 2 diabetes from The Diabetes Centre of the Royal Prince Alfred Hospital were recruited to take part in this study, representing 90% of patients from this ethnic group during the recruitment period. They were all born outside Australia and still lived an Asian lifestyle although now residing in a western country. They were divided into two groups according to whether they had the metabolic syndrome. IDF metabolic syndrome criteria were used preferentially as the specific Chinese waist circumference measurement was available. 3 Analysis using ATP III and WHO metabolic syndrome criteria was also performed. 4, 5 As the prevalence of metabolic syndrome increases with age, only patients older than 50 years were included to improve the accuracy of the assignment. Three patients with renal impairment and two taking glucocorticoids or vitamin D were excluded.
Demographic and clinical data were collected from each patient, including the extent of their exposure to sunlight and time spent watching television. Blood samples were collected for measurements of 25 (OH) vitamin D, PTH, HbA1c, calcium, phosphate, ferritin and hsCRP. A spot urine sample was also taken for testing of microalbuminuria. Vitamin D deficiency was defined as a level ≤ 50 nmol/L, according to the recommendation of the Australian and New Zealand Bone and Mineral Society. 6 Vitamin D was measured by Nicoll's method; PTH was measured by a two site radioimmunoassay (DiaSorin, Stillwater, MN, USA) ferritin and hsCRP were measured by enzyme-linked immunosorbent assay.
Twenty-one of the 39 patients identified to be vitamin D deficient were treated with vitamin D3 tablets (cholecalciferol) 2,000 IU daily for three months. Subjects not recruited were due to non-availability and were not followed further for the purpose of this study. Blood samples were collected at baseline and at monthly intervals for measurement of 25 (OH) vitamin D, PTH, calcium and phosphate.
Data was analysed using NCSS 2004. Continuous data were checked for normality and presented as mean±SD or median and IQR. Categorical data were compared by the chi-square test. The data were grouped according to vitamin D level < 50 and ≥ 50 nmol/L. These groups were compared using two-sample t-test, Mann Whitney U test or chi-square test. Subjects with a low vitamin D were treated with vitamin D supplement and a paired t-test or Wilcoxon signed-rank test was used to test the difference. Pearson's coefficient was used to assess the relationship between vitamin D and metabolic syndrome, inflammatory markers and BMI. Statistical significance was accepted at p < 0.05.
Results

There is no association between hypovitaminosis D and adiposity or the metabolic syndrome within established type 2 diabetes
Hypovitaminsosis D was a common finding in this cohort affecting approximately one third of individuals. Notably age, duration of diabetes, gender, BMI or waist measurements were comparable between the vitamin D-deficient and -sufficient group (Table 1) . There was no difference in the season in which the samples were drawn, and hours of television watched as a surrogate for physical activity between the vitamin D groups. Although PTH levels were not significantly different between the groups, there was a significant increase in the PTH:vitamin D ratio in the hypovitaminosis D group, suggesting functionally significant vitamin D deficiency and appropriate metabolic regulation. Hypovitaminosis D was not associated with the prevalence of the metabolic syndrome as a dichotomous variable, by any definition (Table 1 ). Furthermore, there was no dosedependent effect seen when the number of metabolic syndrome variables present were examined by vitamin D levels using IDF metabolic syndrome factors (Figure 1 ) or other metabolic syndrome definitions. Table 2 shows the individual metabolic and glycaemic parameters by vitamin D status, with no impact seen on overall glycaemic control, number of hypoglycaemic medications used or individual metabolic syndrome parameters.
There is no impact of hypovitaminosis D on metabolic or glycaemic control or on markers of systemic inflammation
Similarly, ferritin and hsCRP levels did not differ between the vitamin D groups ( Table 2) . When examined as a continuous variable, there is no relationship between vitamin D and these markers (Figure 2) , nor was there a relationship between serum AST (as an independent marker of insulin resistance) and vitamin D status. No predictors of vitamin D using the variables of age, gender, HbA1c, BMI, triglycerides, HDL, ACR, ferritin or hsCRP were found.
Effect of adiposity and presence of the metabolic syndrome on response to Vitamin D
When examined as a single continuous variable there was no association between BMI and baseline vitamin D levels (p = 0.6). No significant difference in response to vitamin D supplements was found in those with the metabolic syndrome or those who did not fulfil the classification. There was on average approximately a doubling of vitamin D level after three months of treatment but BMI did not affect the incremental rise in vitamin D levels (Figure 3 ). There was also no change in measurements of hsCRP, ferritin, iron and liver enzymes as a result of vitamin D supplementation.
Discussion
The increasing burden of type 2 diabetes has spawned a search for potentially modifiable environmental factors in an attempt to prevent the disease. Basic science studies revealing the pleiotropic effects of vitamin D on calcium metabolism, insulin secretion and insulin action as well as being an easily administered agent, have made vitamin D an ideal candidate for modulating the development of the metabolic syndrome and type 2 diabetes. However, our data show that within established type 2 diabetes, despite a common finding of vitamin D deficiency, hypovitaminosis D is not associated with increased prevalence of the metabolic syndrome, either as a categorical variable or with a number of metabolic syndrome factors present as a continuous variable. Neither is there any relationship between vitamin D levels and glycaemic control or cellular inflammation.
Our data differ from the data of large-scale observational studies, which show a consistent inverse association between vitamin D level 2 or vitamin D intake 7 on the metabolic syndrome, incidence of type 2 diabetes or surrogate indices. However, these studies examined mainly healthy individuals and did not determine if these metabolic relationships still Data are in median and IQR or as mean ± SD Figure 1 . Relationship between number of IDF metabolic syndrome factors and median vitamin D Data are presented as mean ± SD existed for patients with established diabetes. By contrast, the patient group in our study had diabetes of over 7 years duration. Our data therefore show that the previously reported associations between low vitamin D level and the metabolic syndrome and glycaemia are not seen within established type 2 diabetes. Similarly our findings of a lack of a relationship between vitamin D and hsCRP and ferritin as inflammatory markers are consistent with our metabolic syndrome findings. Both elevated ferritin and hsCRP levels have been associated with the metabolic syndrome and cardiovascular risk in other studies. There is evidence from in vitro studies that vitamin D may modulate inflammatory cytokines and thus affect insulin sensitivity and beta cell survival, however, there are few studies that report on inflammatory markers in relation to vitamin D status in diabetes. In a placebo controlled study by Pittas et al., 8 combined calcium and vitamin D supplementation in those with impaired fasting glucose did not alter hsCRP or interleukin 6 levels. It is likely therefore that vitamin D may not exert its immuno-modulatory effect via these molecules. Our findings suggest that low vitamin D has no clinical impact on metabolic control in type 2 diabetes and correction of vitamin D deficiency would not have great clinical utility as a diabetes therapeutic agent in established diabetes. Perhaps because the inflammatory mechanisms are already maximally stimulated by the diabetic milieu or the beta cell dysfunction, and insulin resistance is more severe and less reversible by the time of established diabetes. The optimum vitamin D level for metabolic outcomes has not been defined and it is notable that the vitamin D levels in the deficient group are still only mildly to moderately reduced. There are only a few reported intervention trials 
Figure 2. Relationship between vitamin D and inflammatory markers
using vitamin D supplementation in established type 2 diabetes. [9] [10] [11] Most were of short duration and in vitaminsufficient individuals; they generally showed no effect on glycaemia or insulin-resistant parameters. However, one trial did show a benefit in only those with diabetes of short duration. Most recently low dose vitamin D supplementation did not affect incident diabetes or parameters of glucose metabolism in the predominantly Caucasian Women's Health Initiative cohort. 12 Potentially, it is possible that much higher vitamin D excursions at an earlier stage of diabetes are required to see a significant impact on metabolic control. One of the criticisms of the epidemiological studies linking low vitamin D levels with the metabolic syndrome is the fact that vitamin D is fat soluble and these associations may be simply representative of the larger volume of distribution of the vitamin in fatter individuals who are also prone to diabetes and metabolic syndrome by virtue of their adiposity. 13 Thus low vitamin D levels may simply cosegregate with adiposity, physical inactivity and ageing with their associated metabolic correlates without necessarily having a significant role in pathogenesis. However, it is interesting to note that hypovitaminosis D in this Chinese population occurs independently of adiposity and cannot be a confounder of obesity. The BMI in our population was lower than one would expect to see in American populations and perhaps this is why our data differed from the larger observational studies. This is suggestive that the vitamin D associations seen in the large-scale intervention trials are an epiphenomenon of adiposity, or perhaps that low vitamin D only manifests as clinically significant in the presence of severe adiposity. However, we were not able to demonstrate an inverse relationship between BMI and vitamin D response during supplementation.
Of course ethnicity may have a role to play here. Previous observational studies included few Asians and as vitamin D associations have previously been found to be ethnic specific, perhaps this is due to differences in calcium homeostasis 14 or differing vitamin D receptor polymorphisms. 14 Our findings may not therefore be generalisable to other populations.
In summary, there is no relationship between hypovitaminosis D and metabolic syndrome status or glycaemic control in well-established Chinese type 2 diabetes. This finding differs from epidemiological studies which show a strong vitamin D relationship with these variables. Future vitamin D intervention trials should focus on prevention and the pre-diabetic state as our data suggests that the effect of low vitamin D is not likely to be clinically significant once diabetes is established, at least in Chinese populations. 
